Compare FTAI Aviation Ltd (FTAI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Neurocrine Biosciences Inc — how do they compare? FTAI Aviation Ltd trades at $169.97 (market cap $17.57B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: FTAI Aviation Ltd is the larger of the two by market cap, and FTAI Aviation Ltd pays a 1.17% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 23 Days and Neurocrine Biosciences Inc for 23 Days on average.
| FTAI | NBIX | |
|---|---|---|
Market Cap | $17.57B | $14.36B |
Volume | 1,905,014 | 1,237,180 |
Sector | Industrials | Health |
52-Week High | $310.04 | $185.50 |
52-Week Low | $152.80 | $123.10 |
Typical Hold Time | 23 Days | 23 Days |
Enterprise Value | $20.69B | $14.37B |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $169.97, down 2.78% with a bearish technical signal despite unanimous analyst buy ratings. The company reported strong 2025 results with $2.51B revenue and $501M net income, though recent quarters missed EPS expectations. Recent developments include a $500M share repurchase program, acquisition of 27 Boeing aircraft, and expanded Asia-Pacific maintenance partnerships, signaling strategic growth initiatives.
FTAI presents a compelling growth story with 100% analyst buy consensus and $321.25 price target representing 89% upside. However, investors face risks from consecutive earnings misses, negative operating cash flow, and declining profit margins. The technical bearish trend and high valuation multiples (P/E 37.35, P/B 43.49) require careful monitoring of execution against growth expectations.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
